{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:51:21Z","timestamp":1790790681515,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40261-020-00886-7","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T07:04:31Z","timestamp":1579935871000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS)"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct03259074","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Readie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SURPASS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,25]]},"reference":[{"key":"886_CR1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.berh.2010.01.005","volume":"24","author":"G Schett","year":"2010","unstructured":"Schett G, Rudwaleit M. Can we stop progression of ankylosing spondylitis? Best Pract Res Clin Rheum. 2010;24:363\u201371.","journal-title":"Best Pract Res Clin Rheum."},{"key":"886_CR2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978\u201391.","journal-title":"Ann Rheum Dis."},{"key":"886_CR3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/ard.2006.066415","volume":"66","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Rudwaleit M. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007;66:910\u20135.","journal-title":"Ann Rheum Dis."},{"key":"886_CR4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/key128","volume":"58","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Braun J, Deodhar A, Baraliakos X, Landewe R, Richards HB, et al. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology (Oxford). 2019;58:388\u2013400.","journal-title":"Rheumatology (Oxford)."},{"key":"886_CR5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/BOR.0000000000000025","volume":"26","author":"GH Louie","year":"2014","unstructured":"Louie GH, Ward MM. Measurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trials. Curr Opin Rheumatol. 2014;26:145\u201350.","journal-title":"Curr Opin Rheumatol."},{"key":"886_CR6","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.20446","volume":"50","author":"AJ Wanders","year":"2004","unstructured":"Wanders AJ, Landew\u00e9 RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum. 2004;50:2622\u201332.","journal-title":"Arthritis Rheum."},{"key":"886_CR7","first-page":"2048","volume":"32","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Landewe R. Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT. J Rheumatol. 2005;32:2048\u20139.","journal-title":"J Rheumatol."},{"key":"886_CR8","first-page":"249","volume":"51","author":"SA Shaikh","year":"2007","unstructured":"Shaikh SA. Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment. J Can Chiropr Assoc. 2007;51:249\u201360.","journal-title":"J Can Chiropr Assoc."},{"key":"886_CR9","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/art.30393","volume":"63","author":"P Chiowchanwisawakit","year":"2011","unstructured":"Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych WP. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum. 2011;63:2215\u201325.","journal-title":"Arthritis Rheum."},{"key":"886_CR10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.24132","volume":"60","author":"WP Maksymowych","year":"2009","unstructured":"Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, \u00d8stergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum. 2009;60:93\u2013102.","journal-title":"Arthritis Rheum."},{"key":"886_CR11","doi-asserted-by":"crossref","first-page":"R104","DOI":"10.1186\/ar2496","volume":"10","author":"X Baraliakos","year":"2008","unstructured":"Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthitis Res Ther. 2008;10:R104.","journal-title":"Arthitis Res Ther."},{"key":"886_CR12","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3899\/jrheum.100925","volume":"38","author":"SJ Pedersen","year":"2011","unstructured":"Pedersen SJ, Chiowchanwisawakit P, Lambert RG, \u00d8stergaard M, Maksymowych WP. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol. 2011;38:1349\u201354.","journal-title":"J Rheumatol."},{"key":"886_CR13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, Ermann J, Gensler LS, Smith JA, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68:282\u201398.","journal-title":"Arthritis Rheumatol."},{"key":"886_CR14","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Heijde D, Landewe R. Nonosteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756\u201365.","journal-title":"Arthritis Rheum."},{"key":"886_CR15","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2\u00a0years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75:1438\u201343.","journal-title":"Ann Rheum Dis."},{"key":"886_CR16","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landew\u00e9 R, Baraliakos X. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063\u201370.","journal-title":"Arthritis Rheum."},{"key":"886_CR17","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landew\u00e9 R, Einstein S. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324\u201331.","journal-title":"Arthritis Rheum."},{"key":"886_CR18","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Salonen D, Weissman BN. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2\u00a0years. Arthritis Res Ther. 2009;11:R127.","journal-title":"Arthritis Res Ther."},{"key":"886_CR19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/acr.23097","volume":"69","author":"F Maas","year":"2017","unstructured":"Maas F, Arends S, Brouwer E, Essers I, Van der Veer E, Efde M, et al. Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res. 2017;69:1011\u20139.","journal-title":"Arthritis Care Res."},{"key":"886_CR20","doi-asserted-by":"crossref","first-page":"e0177231","DOI":"10.1371\/journal.pone.0177231","volume":"12","author":"F Maas","year":"2017","unstructured":"Maas F, Arends S, Wink FR, Bos R, Bootsma H, Brouwer E, et al. Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-\u03b1 inhibitors. PLoS One. 2017;12:e0177231.","journal-title":"PLoS One."},{"key":"886_CR21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","volume":"11","author":"E Lubberts","year":"2015","unstructured":"Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11:415\u201329.","journal-title":"Nat Rev Rheumatol."},{"key":"886_CR22","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.23233","volume":"69","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study. Arthritis Care Res. 2017;69:1020\u20139.","journal-title":"Arthritis Care Res."},{"key":"886_CR23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M. Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N Engl J Med. 2014;371:326\u201338.","journal-title":"N Engl J Med."},{"key":"886_CR24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137\u201346.","journal-title":"Lancet."},{"key":"886_CR25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329\u201339.","journal-title":"N Engl J Med."},{"key":"886_CR26","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705\u201313.","journal-title":"Lancet."},{"key":"886_CR27","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534\u201348.","journal-title":"N Engl J Med."},{"key":"886_CR28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","volume":"19","author":"K Pavelka","year":"2017","unstructured":"Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19:285.","journal-title":"Arthritis Res Ther."},{"key":"886_CR29","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76:1070\u20137.","journal-title":"Ann Rheum Dis."},{"key":"886_CR30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","volume":"58","author":"J Braun","year":"2018","unstructured":"Braun J, Baraliakos X, Deodhar AA, Poddubnyy D, Emery P, Delicha EM, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology. 2018;58:859\u201368.","journal-title":"Rheumatology."},{"key":"886_CR31","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2015-207544","volume":"75","author":"X Baraliakos","year":"2016","unstructured":"Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016;75:408\u201312.","journal-title":"Ann Rheum Dis."},{"key":"886_CR32","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol."},{"key":"886_CR33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.2004.020503","volume":"64","author":"MC Creemers","year":"2005","unstructured":"Creemers MC, Franssen MJ, van\u2019t Hof MA. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64:127\u20139.","journal-title":"Ann Rheum Dis."},{"key":"886_CR34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.rdc.2016.07.006","volume":"42","author":"X Baraliakos","year":"2016","unstructured":"Baraliakos X, Braun J. Imaging scoring methods in axial spondyloarthritis. Rheum Dis Clin N Am. 2016;42:663\u201378.","journal-title":"Rheum Dis Clin N Am."},{"key":"886_CR35","unstructured":"EMA. Guideline on missing data in confirmatory clinical trials. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-missing-data-confirmatory-clinical-trials_en.pdf. Accessed 24 Sep 2019."},{"key":"886_CR36","first-page":"2075","volume":"70","author":"AJ Kivitz","year":"2018","unstructured":"Kivitz AJ, Pavelka K, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, et al. Sustained improvements in signs and symptoms of active ankylosing spondylitis and reassuring safety with secukinumab 300 mg: 3-year results from a phase 3 study [abstract]. Arthritis Rheumatol. 2018;70:2075.","journal-title":"Arthritis Rheumatol."},{"key":"886_CR37","doi-asserted-by":"crossref","first-page":"e000592","DOI":"10.1136\/rmdopen-2017-000592","volume":"3","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open. 2017;3:e000592.","journal-title":"RMD Open."},{"key":"886_CR38","first-page":"125","volume":"31","author":"A Spoorenberg","year":"2004","unstructured":"Spoorenberg A, de Vlam K, van der Linden S. Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2\u00a0years. J Rheumatol. 2004;31:125\u201332.","journal-title":"J Rheumatol."},{"key":"886_CR39","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/art.24425","volume":"61","author":"X Baraliakos","year":"2009","unstructured":"Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. Development of a radiographic scoring tool for ankylosing spondylitis only based on the bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum. 2009;61:764\u201371.","journal-title":"Arthritis Rheum."},{"key":"886_CR40","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","volume":"73","author":"S Ramiro","year":"2014","unstructured":"Ramiro S, van der Heijde D, van Tubergen A. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73:1455\u201361.","journal-title":"Ann Rheum Dis."},{"key":"886_CR41","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","volume":"64","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Haibel H, Listing J. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64:1388\u201398.","journal-title":"Arthritis Rheum."},{"key":"886_CR42","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","volume":"71","author":"F Kroon","year":"2012","unstructured":"Kroon F, Landewe R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:1623\u20139.","journal-title":"Ann Rheum Dis."},{"key":"886_CR43","doi-asserted-by":"crossref","first-page":"e0122693","DOI":"10.1371\/journal.pone.0122693","volume":"10","author":"F Maas","year":"2015","unstructured":"Maas F, Spoorenberg A, Brouwer E. Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-a blocking therapy: a prospective longitudinal observational cohort study. PLos One. 2015;10:e0122693.","journal-title":"PLos One."},{"key":"886_CR44","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3899\/jrheum.080871","volume":"36","author":"X Baraliakos","year":"2009","unstructured":"Baraliakos X, Listing J, von der Recke A, Braun J. The natural course of radiographic progression in ankylosing spondylitis evidence for major individual variations in a large proportion of patients. J Rheumatol. 2009;36:997\u20131002.","journal-title":"J Rheumatol."},{"key":"886_CR45","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44:1876\u201386.","journal-title":"Arthritis Rheum."},{"key":"886_CR46","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O\u2019Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281\u20135.","journal-title":"J Rheumatol."},{"key":"886_CR47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47\u201353.","journal-title":"Ann Rheum Dis."},{"key":"886_CR48","volume-title":"How to score version 2 of the SF-36 health survey","author":"J Ware","year":"2001","unstructured":"Ware J, Kosinski M, Dewey JE. How to score version 2 of the SF-36 health survey. Lincoln: QualityMetric, Incorporated; 2001."},{"key":"886_CR49","volume-title":"Version 2 of the SF-36 health survey","author":"J Ware","year":"2003","unstructured":"Ware J, Kosinski M, Dewey JE. Version 2 of the SF-36 health survey. Lincoln: QualityMetric, Incorporated; 2003."},{"key":"886_CR50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.62.1.20","volume":"62","author":"LC Doward","year":"2003","unstructured":"Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003;62:20\u20136.","journal-title":"Ann Rheum Dis."},{"key":"886_CR51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13:63\u201374.","journal-title":"J Pain Symptom Manag."},{"key":"886_CR52","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353\u201365.","journal-title":"PharmacoEconomics."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00886-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00886-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00886-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:45:51Z","timestamp":1628617551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00886-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,25]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["886"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00886-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,25]]},"assertion":[{"value":"25 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study was funded by Novartis Pharma AG, Basel.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M\u00d8 has received research support and\/or consultancy\/speaker fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Contocor, Eli-Lilly, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo Nordisk, Orion, Pfizer, Regeneron, Roche, Schering-Plough, Takeda, UCB and Wyeth. UK has received grant and research support and consultancy fees from AbbVie, Biocad, Biogen, Chugai, Eli Lilly, Gr\u00fcnenthal, Janssen, MSD, Novartis, Pfizer, Roche and UCB. DP reports grants and personal fees from AbbVie, personal fees from BMS, personal fees from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Roche, personal fees from UCB, personal fees from Celgene, grants or consulting fees from Janssen, outside the submitted work. LG has received grant\/research support from UCB, AbbVie, Amgen, Novartis, Pfizer; and consulting fees from Galapagos, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. XB and EYL has no conflicts of interest to disclose. BP, RM, AR and HS are employees and shareholders of Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was designed and will be implemented, executed reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations, and with the ethical principles laid down in the Declaration of Helsinki. The study was approved by the institutional review boards or independent ethics committees at each participating center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}